15:55:51 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande



2024-11-21 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-30 Kvartalsrapport 2024-Q1
2024-05-24 Ordinarie utdelning 2CUREX 0.00 SEK
2024-05-23 Årsstämma 2024
2024-02-29 Extra Bolagsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2023-11-23 Kvartalsrapport 2023-Q3
2023-11-14 Extra Bolagsstämma 2023
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-29 Kvartalsrapport 2023-Q1
2023-05-26 Ordinarie utdelning 2CUREX 0.00 SEK
2023-05-25 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2023-02-10 Extra Bolagsstämma 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-25 Ordinarie utdelning 2CUREX 0.00 SEK
2022-05-24 Kvartalsrapport 2022-Q1
2022-05-24 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-28 Ordinarie utdelning 2CUREX 0.00 SEK
2021-05-27 Årsstämma 2021
2021-05-27 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-26 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-07-02 Extra Bolagsstämma 2020
2020-05-29 Ordinarie utdelning 2CUREX 0.00 SEK
2020-05-28 Kvartalsrapport 2020-Q1
2020-05-28 Årsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2019-11-22 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-29 Ordinarie utdelning 2CUREX 0.00 SEK
2019-05-28 Årsstämma 2019
2019-05-17 Kvartalsrapport 2019-Q1
2019-04-02 Extra Bolagsstämma 2019
2019-03-01 Bokslutskommuniké 2018
2018-11-23 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-05-29 Ordinarie utdelning 2CUREX 0.00 SEK
2018-05-28 Årsstämma 2018
2018-05-18 Kvartalsrapport 2018-Q1
2018-02-15 Bokslutskommuniké 2017


ListaFirst North Stockholm
2cureX är verksamma inom cancerbehandling. Idag tillhandahåller bolaget olika verktyg som används av läkare vid behandlingar för att mäta effekt och resistens hos cancerläkemedel på patientens egna cancerceller. Målet är att förkorta behandlingsperioden samt hitta rätt individuell behandling. Idag innehas störst verksamhet på den europeiska marknaden. Huvudkontoret ligger i Köpenhamn.
2023-08-30 08:30:00

2cureX announced today the launch of two IVD products – IndiTreat® Specimen Collection Kit and IndiTreat® Shipping Container – that have become the first to be CE-marked under the new IVD-R by the company. The IndiTreat® Specimen Collection Kit is a replacement of the previous IndiTreat® Specimen Collection Set, while the IndiTreat® Shipping Container is a new device to ensure optimal conditions during transportation of patient samples from hospitals to the 2cureX testing facilities.

The IndiTreat® test is performed on patient-derived 3D tumoroids that are biological replicas of the patient’s original tumor. To grow these 3D tumoroids, it is essential that the biopsy taken from the patient reaches the 2cureX testing facilities in optimal conditions.

The IndiTreat® Specimen Collection Kit contains a specialized ready-to-use, single-use buffer capable of supporting the viability of specimen samples during transportation, as well as a temperature logging device to monitor the temperature that the specimen has been exposed to during shipment. The IndiTreat® Shipping Container is a specialized single-use shipping container capable of supporting specimens with optimal shipping conditions by providing stable temperatures within 2-8°C in the sealed payload compartment for at least 48 hours.

The two new products will start to be commercialized immediately throughout the 20 countries where 2cureX has commercial operations, directly or through its network of distribution partnerships. Today’s news are in line with our launching plans for 2023, and will not affect our revenue expectations for the year.

A critical step of the process

“We are very proud of this launch”, says Jacob Thastrup, Director of Product Development at 2cureX. And continues “These two products combined ensure the required control and traceability during transport, which is a critical step of the process. Furthermore, this CE-marking shows the progress we have made in terms of our readiness for IVD-R, where the requirements for the development and documentation of the product are much more stringent than they were in the past”.

First to market

“As far as we know, 2cureX has been the first among all players in the Functional Drug Sensitivity Testing field to CE-Mark under IVD-R the components for sample transportation”, says Fernando Andreu, CEO of 2cureX. “This is a testimony to our leadership in this space, and to the effort of our team in turning the challenge of the European regulatory changes into an opportunity for differentiation”.

New regulation

The new Regulation (EU) 2017/746 (IVD-R) rules the placing on the market and putting into service of in vitro diagnostic medical devices (IVD), replacing Directive 98/79/EC (IVD-D). The regulation entered into full force on May 26th, 2022, and its main changes relate to device classification, stricter oversight of manufacturers by Notified Bodies, introduction of the "Person Responsible for Regulatory Compliance" (PRRC), the requirement of UDI marking for devices, common specifications, Eudamed registration, and increased post-market surveillance activities.

For more information about 2cureX:

Fernando Andreu, Chief Executive Officer
E-mail: fa@2curex.com
Telephone: +45 2279 5399

About 2cureX

2cureX is a leader in cancer drug sensitivity profiling and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different drugs available, providing the physician with valuable information to make treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer - IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line. Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX").

For more information about 2cureX visit www.2curex.com

Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se